In this latest instalment of Bell Direct’s From the helm series, we kick off 2025 with an exciting deep dive into the healthcare sector. Host Bell Direct’s Market Analyst, Grady Wulff sits down with Opthea (ASX:OPT) CEO, Fred Guerard to discuss the company’s remarkable 168% share price surge over the past six months as it advances toward commercialising its novel retinal disease treatment, Sozinibercept. With an initial focus on wet age-related macular degeneration, Opthea is poised to disrup...

Folgen-ID: 1000689763639

GUID: Buzzsprout-16577842

Erscheinungs­datum: 6.2.2025, 23:00:00